Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Harold R. Collard(University of California, San Francisco), Kevin K. Brown(Health Protection Surveillance Centre), Becki Bucher Bartelson(San Francisco General Hospital), Jason S. Vourlekis(San Francisco General Hospital), Talmadge E. King(University of California, San Francisco), Marvin I. Schwarz(San Francisco General Hospital)
Cited by 762
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
|The Lancet|2011|2.1k
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
|New England Journal of Medicine|2011|1.1k